文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

急性心肌梗死后的动脉粥样硬化血栓形成风险分层:鉴于法国急性ST段抬高或非ST段抬高型心肌梗死注册研究,心肌梗死溶栓治疗二级预防风险评分。

Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries.

作者信息

Puymirat Etienne, Bonaca Marc, Fumery Maxime, Tea Victoria, Aissaoui Nadia, Lemesles Gilles, Bonello Laurent, Ducrocq Grégory, Cayla Guillaume, Ferrières Jean, Schiele François, Simon Tabassome, Danchin Nicolas

机构信息

Department of Cardiology, Hôpital Européen Georges Pompidou (HEGP), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Division of Cardiovascular Medicine, TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

出版信息

Clin Cardiol. 2019 Feb;42(2):227-234. doi: 10.1002/clc.23131. Epub 2018 Dec 27.


DOI:10.1002/clc.23131
PMID:30536449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6712320/
Abstract

BACKGROUND: Guidelines recommend using risk stratification tools in acute myocardial infarction (AMI) to assist decision-making. The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P) has been recently developed to characterize long-term risk in patients with MI. HYPOTHESIS: We aimed to assess the TRS-2P in the French Registry of Acute ST Elevation or non-ST elevation MI registries. METHODS: We used data from three 1-month French registries, conducted 5 years apart, from 2005 to 2015, including 13 130 patients with AMI (52% ST-elevation myocardial infarction [STEMI]). Atherothrombotic risk stratification was performed using the TRS-2P score. Patients were divided in to three categories: G1 (low-risk, TRS-2P = 0/1); G2 (intermediate-risk, TRS-2P = 2); and G3 (high-risk, TRS-2P ≥ 3). Baseline characteristics and outcomes were analyzed according to TRS-2P categories. RESULTS: A total of 12 715 patients (in whom TRS-2P was available) were included. Prevalence of G1, G2, and G3 was 43%, 24%, and 33% respectively. Clinical characteristics and management significantly differed according to TRS-2P categories. TRS-2P successfully defined residual risk of death at 1 year (C-statistic 0.78): 1-year survival was 98% in G1, 94% in G2, and 78.5% in G3 (P < 0.001). Using Cox multivariate analysis, G3 was independently associated with higher risk of death at 1 year (hazard ratio [HR] 4.61; 95% confidence interval [CI]: 3.61-5.89), as G2 (HR 2.08; 95% CI: 1.62-2.65) compared with G1. The score appeared robust and correlated well with mortality in STEMI and NSTEMI populations, as well as in each cohort separately. CONCLUSIONS: The TRS-2P appears to be a robust risk score, identifying patients at high risk after AMI irrespective of the type of MI and historical period.

摘要

背景:指南建议在急性心肌梗死(AMI)中使用风险分层工具来辅助决策。最近开发了心肌梗死二级预防溶栓风险评分(TRS - 2P)以描述心肌梗死患者的长期风险。 假设:我们旨在评估法国急性ST段抬高或非ST段抬高心肌梗死注册研究中的TRS - 2P。 方法:我们使用了来自法国三个为期1个月的注册研究的数据,这些研究在2005年至2015年期间相隔5年进行,包括13130例AMI患者(52%为ST段抬高型心肌梗死[STEMI])。使用TRS - 2P评分进行动脉粥样硬化血栓形成风险分层。患者分为三类:G1(低风险,TRS - 2P = 0/1);G2(中风险,TRS - 2P = 2);G3(高风险,TRS - 2P≥3)。根据TRS - 2P类别分析基线特征和结局。 结果:共纳入12715例患者(可获得TRS - 2P)。G1、G2和G3的患病率分别为43%、24%和33%。临床特征和管理根据TRS - 2P类别有显著差异。TRS - 2P成功定义了1年时的死亡残余风险(C统计量0.78):G1组1年生存率为98%,G2组为94%,G3组为78.5%(P < 0.001)。使用Cox多变量分析,与G1组相比,G3组在1年时独立与更高的死亡风险相关(风险比[HR] 4.61;95%置信区间[CI]:3.61 - 5.89),G2组也是如此(HR 2.08;95% CI:1.62 - 2.65)。该评分似乎很稳健,并且与STEMI和NSTEMI人群以及每个队列单独的死亡率相关性良好。 结论:TRS - 2P似乎是一个稳健的风险评分,可识别AMI后高危患者,无论心肌梗死类型和历史时期如何。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/6712320/9f43e3b4bfa7/CLC-42-227-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/6712320/2e160d3b2495/CLC-42-227-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/6712320/9f43e3b4bfa7/CLC-42-227-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/6712320/2e160d3b2495/CLC-42-227-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3bde/6712320/9f43e3b4bfa7/CLC-42-227-g002.jpg

相似文献

[1]
Atherothrombotic risk stratification after acute myocardial infarction: The Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention in the light of the French Registry of Acute ST Elevation or non-ST Elevation Myocardial Infarction registries.

Clin Cardiol. 2019-2

[2]
Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry.

Eur J Prev Cardiol. 2018-10-24

[3]
Clinical outcomes with high-intensity statins according to atherothrombotic risk stratification after acute myocardial infarction: The FAST-MI registries.

Arch Cardiovasc Dis. 2021-2

[4]
Outcome associated with prescription of cardiac rehabilitation according to predicted risk after acute myocardial infarction: Insights from the FAST-MI registries.

Arch Cardiovasc Dis. 2019-5-22

[5]
Long-Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention.

J Am Heart Assoc. 2019-7-4

[6]
In-hospital outcomes and 5-year mortality following an acute myocardial infarction in patients with a history of cancer: Results from the French registry on Acute ST-elevation or non-ST-elevation myocardial infarction (FAST-MI) 2005 cohort.

Arch Cardiovasc Dis. 2019-11-21

[7]
Prognostic impact of prepercutaneous coronary intervention TIMI flow in patients with ST-segment and non-ST-segment elevation myocardial infarction: Results from the FAST-MI 2010 registry.

Arch Cardiovasc Dis. 2017-9-19

[8]
Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015.

Circulation. 2017-8-27

[9]
TIMI risk score for secondary prevention of recurrent cardiovascular events in a real-world cohort of post-non-ST-elevation myocardial infarction patients.

Postgrad Med J. 2019-5-23

[10]
French Registry on Acute ST-elevation and non-ST-elevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data.

Arch Cardiovasc Dis. 2017

引用本文的文献

[1]
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.

J Atheroscler Thromb. 2024-6-1

[2]
Cholesterol goals, statin use and residual cardiovascular risk estimated by SMART score: Study of a Nicaraguan population.

Int J Cardiol Cardiovasc Risk Prev. 2023-6-23

[3]
NLRP3 Inflammasome May Be a Biomarker for Risk Stratification in Patients with Acute Coronary Syndrome.

J Inflamm Res. 2022-12-6

[4]
Management and outcomes over time of acute coronary syndrome patients at particularly high cardiovascular risk : the ACSIS registry-based retrospective study.

BMJ Open. 2022-4-11

[5]
Correlation Between TIMI Risk Score and the Number of Vessels Involved in the Angiographic Study; a Cross-sectional Study.

Arch Acad Emerg Med. 2022-2-14

[6]
Environmental noise exposure is associated with atherothrombotic risk.

Sci Rep. 2022-2-24

[7]
Untargeted high-resolution plasma metabolomic profiling predicts outcomes in patients with coronary artery disease.

PLoS One. 2020-8-18

[8]
Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database.

Cardiol Ther. 2019-12

[9]
Long-Term Risk Stratification of Patients Undergoing Coronary Angiography According to the Thrombolysis in Myocardial Infarction Risk Score for Secondary Prevention.

J Am Heart Assoc. 2019-7-4

本文引用的文献

[1]
External validation of the TIMI risk score for secondary cardiovascular events among patients with recent myocardial infarction.

Atherosclerosis. 2018-3-16

[2]
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC).

Eur Heart J. 2018-1-7

[3]
Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015.

Circulation. 2017-8-27

[4]
French Registry on Acute ST-elevation and non-ST-elevation Myocardial Infarction 2015 (FAST-MI 2015). Design and baseline data.

Arch Cardiovasc Dis. 2017

[5]
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.

N Engl J Med. 2017-3-17

[6]
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.

J Am Coll Cardiol. 2017-2-28

[7]
Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.

Circulation. 2016-7-26

[8]
Long-term use of ticagrelor in patients with prior myocardial infarction.

N Engl J Med. 2015-3-14

[9]
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Circulation. 2014-12-23

[10]
Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score.

BMJ Open. 2014-2-21

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索